We still awaiting detailed data in terms of numbers and statistics to see how 554 performed. First time I have read here that it actually increased FEV by 200 mls as compared to placebo. Sounds excellent to me. Of course we need to know about rest of PFTs.
IMHO they will release this data only with funding news. If they are in a discussion with a partner they won't like detailed data to be out. Let's see what next few weeks brings. Hopefully all will be clear before July. GLA
Thanks all of you for your support. I hope truly we excel like Leicester city. This is old article from fiercebiotech. I never posted it here as it mentions the word placing. There is nothing new what we don't know already. It's clear from last months RNS that we will be looking for money either through grant/partnership/placing. This week mood is good so I thought I will post it here.
London-based Verona talked up the prospects for its PDE3/PDE4 inhibitor RPL554 after posting data from… Read More
Thanks izstar for your support. Clearly I'm not here just jumping up and down with sp movement. I have contributed some good info in the past without divulging too much details I would like to say most of my investment is in pharma as that's an area of my expertise. I know we are only in phase 2 but look at the data so far. Only positive results and no major side effects. This molecule was discovered after they had tried 200 molecules. The person who discovered it is from imperial college and… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.